News & Insights
Sort By
Insights 1 result
Insights
|November 9, 2017
The Most Important New Privacy Law in a Generation: The GDPR
If you have any questions regarding the matters covered in this client alert, you may contact the following GD attorneys:
Events 1 result
Events
|February 7, 2024
Webinar: “What’s Market” in University Licenses in the Life Science Industry
Gunderson Dettmer Strategic Transactions and Licensing partner Brendan McCarthy hosted the webinar “’What’s Market’ in University Licenses in the Life Sciences Industry” to discuss the key economic terms in university license agreements.
Client News 25 Results
Client News
|May 27, 2025
Cambridge-based biopharmaceutical company pioneering RNAi-based medicine, City Therapeutics, announces its $ 1 billion strategic collaboration with Biogen Inc., a company focused on pioneering innovative science to deliver new medicines
Client News
|January 10, 2025
City Therapeutics Enters Strategic Collaboration with Bausch + Lomb
City Therapeutics, a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, announces its strategic collaboration with global eye health leader, Bausch + Lomb
Client News
|October 8, 2024
City Therapeutics Announces Launch with $135M Series A Financing
City Therapeutics announces its launch and $135 million Series A financing led by ARCH Ventures
Firm News 1 result
Firm News
|December 13, 2018
Gunderson Dettmer Announces New Partners
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP has announced the promotions of five associates to the partnership, effective January 1, 2019.